Tempus has joined an elite group of private startup companies, as it is now officially a unicorn. Eric Lefkofsky, cofounder and Chief Executive Officer of Tempus shared information on the string of investments received by the company since 2015. During the Series A and B Rounds, Tempus received $ 30 million in investments. In April 2017 the data company received an additional $ 30 million in investments. During Series Round C, considered the late stage venture round, Tempus secured $ 70 million. Large investments are made to startups that have proven the ability to withstand hardships and in the long run turn a profit. Tempus received $ 70 million during Round C, and in March 2018 Tempus received an additional $ 80 million. It is estimated the healthcare data analytical company is now worth $ 1.1 billion. Kinship Trust, T. Rowe Price Associates, New Enterprise Associates and Revolution Growth are among the investors responsible for the bulk of the funding acquired. Eric Lefkoksky said the funding received from investments is used primarily to hire new employees, and they add on average about 30 new positions each month.
Tempus is a healthcare information technology company that uses data analysis to fight cancer. Eric Lefkofsky said Tempus’s approach is cutting edge, because for the first time we have access to large organized sets of data. By applying machine learning algorithms to historical healthcare data, healthcare professionals are able to identify effective treatments and apply them based on the real time molecular data from cancer tumors.
Eric Lefkofsky is also cofounder of Groupon, Mediaocean, Innerworking, Echo Global Logistics and UpTake Technologies. UpTake is a data analytical company that use predictive artificial intelligence to help investors make sound financial plan based on historical economic data. A graduate of the University of Michigan, Mr. Lefkofsky is also on the Board of Trustees of the Chicago Steppenwolf Theater Company, and a Trustee of Lurie’s Children’s Hospital in Chicago.
There are very few companies that provide care to patients and treat their employees right. At Sussex Healthcare, it is the best of both worlds. Patients receive award winning healthcare, while the staff that looks after them get competitive wages. This is a win win for everyone.
So who is responsible for the success of such a wonderful marketed company? Look no further than Shafik Sachedina and Shiraz Boghani. These men are not only chairmen but the brains behind Sussex Healthcare. A business that started out as one facility, is now 20. This duo combined their skills to form such an amazing healthcare network. With a nice gym, daycare, and residential housing that provides full care, no wonder they were awarded for sheer excellence in the healthcare field.
Bringing Amanda Morgan-Taylor on was a brilliant move. Because she cares about the patient and staff relationships, this helps her to focus on keeping it improved. There is always room to grow some more. Thanks to the staff that shows actual love to the patients and makes them feel very important. Relationships like this are very essential. That keeps the patients alive for as long as possible.
What does Sussex Healthcare provide you ask? They provide services to the elderly and anyone with neurological disabilities. Basically, they help people who can no longer take care of themselves. From Dementia to Alzheimer’s patients, the staff goes beyond to make the patients feel at home. They provide healthy meals from very skilled chefs. The staff also take care of their social well being. According to Sussex Healthcare, all life is worth living. Any patient at the facility will see some improvement utilizing the care that is given them.
What makes the staff at Sussex Healthcare so dedicated to their jobs. It could be that the wages are great. They are given bonus pay for weekend and holiday shifts. There is training provided, along with company perks. Management that looks after their staff can see their company succeed in a way that is jaw dropping. There are board members such as Corrine Wallace, who is the Head of Marketing. Also, Peter Catchpole and Professor Nick Bosanquet are policy advisors.
Amicus Therapeutics recently has its prescription drug approved called Galafold by Health Canada. This oral drug is used to treat a rare disease called Fabry disease. It is a disease that causes a defect in an enzyme in the body. This leads to an excess amount of fat in the body called Gb3 and G-L3. The drug will be available to Canadian patients (https://seekingalpha.com/article/4073303-amicus-therapeutics-small-biotech-seems-big-mo).
This is a positive step for Canadians suffering from this disease said John F. Crowley, Chairman, and Chief Executive Officer. The company looks forward to making the medication accessible to other countries. The drug works by stabilizing the enzyme so that it clears the body of the fat buildup.
The drug was approved after several clinical trials. Dr. Daniel Bichet from the University of Montreal said that after years of treating a patient with Fabry disease he was glad to see the drug approved. There are many people that will benefit from treatment from this drug.
John Crowley, CEO of the company became a biotech entrepreneur to help his two children with a rare disease called Pompe disease. It is a neuro-muscular disease that can be fatal. He became involved in the industry when both children were diagnosed with the disorder. At the time there was no treatment or cures.
Their research leads to a treatment that both children have been on for a decade and lead to saving their lives. The company collaborates with organizations, doctors, patients, and caregivers. They listen and learn about the rare diseases from patients and caregivers. They do extensive research and always look for new and better therapies (Indeed). The company often use patients in clinical studies and help patients manage their daily activities.
The company staff is very passionate about the work they do. The will continue to come up with new innovative treatments for rare diseases in the future.